Clinical trials: B-cell Non Hodgkin Lymphoma
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Diffuse Large B Cell Lymphoma
Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL
This study is a phase I multicenter, single arm, open, dose increasing, single treatment clinical study. This study plans to recruit a total of about 10-16 adult patients with CD19 positive recurrent or refractory DLBCL for a…
- Trial name
- NCT05269914
- Testing
- Autologous anti-CD19 CAR-T cell injection
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Diffuse Large B-cell Lymphoma
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients affected by relapsed/refractory DLBCL…
- Trial name
- NCT04433182
- Testing
- Copanlisib
- Where
- 17 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
This clinical trial evaluates the effects of hemoglobin threshold-specific packed red blood cell (PRBC) transfusions on quality of life and functional outcomes in patients who have undergone chemotherapy or an allogeneic…
- Conditions
- Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
- Trial name
- NCT06710418
- Testing
- Activity Tracking, Biospecimen Collection, Cognitive Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Non-Hodgkin's Lymphoma
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments.
- Trial name
- NCT00323323
- Testing
- CHOP, Alemtuzumab, Plasma Samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma, Non-Hodgkin
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
- Trial name
- NCT05844956
- Testing
- DZD8586
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
B-Cell Acute Lymphoblastic Leukemia, Adult
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04788472
- Testing
- CAR-T cells targeting CD19 and CD22
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang University
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Non-Hodgkin Lymphoma
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
- Trial name
- NCT04296461
- Testing
- Welgenaleucel
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and…
- Trial name
- LOTIS-8 (NCT04974996)
- Testing
- Loncastuximab tesirine, Prednisone, Rituximab
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
DLBCL - Diffuse Large B Cell Lymphoma
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R …
- Trial name
- NCT07389356
- Testing
- Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies.
- Trial name
- NCT04684472
- Testing
- Modified anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liqun Zou
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00387959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Quality of Life
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.
- Trial name
- NCT00098566
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Cachexia, Lymphoma
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053053
- Testing
- Juven, Non-Juven Supplement
- Where
- 250 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Radiation Therapy Oncology Group
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the…
- Trial name
- ARCHED (NCT05820841)
- Testing
- R-miniCHOP + Acalabrutinib, R-miniCHOP
- Where
- 17 sites in Germany
- Volunteers
- 330 people
- Sponsor
- Universität des Saarlandes
Primary Mediastinal Diffuse Large B-cell Lymphoma
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
The goal of this clinical study is to evaluate the efficacy and safety of sintilimab combined with rituximab followed by R-CHOP regimen in treatment-naïve patients with primary mediastinal diffuse large B-cell lymphoma.
- Trial name
- Si-Ri (NCT06742502)
- Testing
- Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- MAJIC (NCT05057494)
- Testing
- Acalabrutinib, Venetoclax, Obinutuzumab
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 607 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.